James Allison

Summary

Affiliation: Memorial Sloan-Kettering Cancer Center
Country: USA

Publications

  1. pmc Limited tumor infiltration by activated T effector cells restricts the therapeutic activity of regulatory T cell depletion against established melanoma
    Sergio A Quezada
    Howard Hughes Medical Institute and the Ludwig Center for Cancer Immunotherapy, Department of Immunology, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    J Exp Med 205:2125-38. 2008
  2. pmc Tumor-reactive CD4(+) T cells develop cytotoxic activity and eradicate large established melanoma after transfer into lymphopenic hosts
    Sergio A Quezada
    Ludwig Center for Cancer Immunotherapy, Howard Hughes Medical Institute, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    J Exp Med 207:637-50. 2010
  3. pmc Tissue-specific expression of B7x protects from CD4 T cell-mediated autoimmunity
    Joyce Wei
    Howard Hughes Medical Institute, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA
    J Exp Med 208:1683-94. 2011
  4. pmc Combination CTLA-4 blockade and 4-1BB activation enhances tumor rejection by increasing T-cell infiltration, proliferation, and cytokine production
    Michael A Curran
    Howard Hughes Medical Institute, Department of Immunology, Memorial Sloan Kettering Cancer Center, New York, New York, United States of America
    PLoS ONE 6:e19499. 2011
  5. pmc Attenuated T cell responses to a high-potency ligand in vivo
    Emily Corse
    Department of Immunology, Howard Hughes Medical Institute and Ludwig Center for Cancer Immunotherapy, Memorial Sloan Kettering Cancer Center, New York, New York, USA
    PLoS Biol 8:. 2010
  6. pmc TCR ligand density and affinity determine peripheral induction of Foxp3 in vivo
    Rachel A Gottschalk
    Department of Immunology, Howard Hughes Medical Institute, New York, NY 10021, USA
    J Exp Med 207:1701-11. 2010
  7. pmc Blockade of CTLA-4 on both effector and regulatory T cell compartments contributes to the antitumor activity of anti-CTLA-4 antibodies
    Karl S Peggs
    Howard Hughes Medical Institute, Department of Immunology, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    J Exp Med 206:1717-25. 2009
  8. pmc Cancer classification using the Immunoscore: a worldwide task force
    Jerome Galon
    INSERM, U872, Laboratory of Integrative Cancer Immunology, Paris, F 75006, France
    J Transl Med 10:205. 2012
  9. pmc Defining the critical hurdles in cancer immunotherapy
    Bernard A Fox
    Earle A, Chiles Research Institute, Robert W, Franz Research Center, Providence Cancer Center, Providence Portland Medical Center, Portland, OR, USA
    J Transl Med 9:214. 2011
  10. pmc SPAS-1 (stimulator of prostatic adenocarcinoma-specific T cells)/SH3GLB2: A prostate tumor antigen identified by CTLA-4 blockade
    Marcella Fassò
    Departments of Urology and Medicine, University of California, San Francisco, CA 94143, USA
    Proc Natl Acad Sci U S A 105:3509-14. 2008

Research Grants

  1. T CELL COSTIMULATION IN ANTITUMOR RESPONSES
    James Allison; Fiscal Year: 2001
  2. High Speed Cell Sorter
    James Allison; Fiscal Year: 2002
  3. SURFACE ANTIGENS OF MURINE T LYMPHOMAS
    James Allison; Fiscal Year: 2008

Collaborators

Detail Information

Publications54

  1. pmc Limited tumor infiltration by activated T effector cells restricts the therapeutic activity of regulatory T cell depletion against established melanoma
    Sergio A Quezada
    Howard Hughes Medical Institute and the Ludwig Center for Cancer Immunotherapy, Department of Immunology, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    J Exp Med 205:2125-38. 2008
    ..The data demonstrate a dissociation between measurable systemic responses and tumor rejection during CD25-directed T reg cell depletion, and suggest an alternative, clinically applicable strategy for the treatment of established tumors...
  2. pmc Tumor-reactive CD4(+) T cells develop cytotoxic activity and eradicate large established melanoma after transfer into lymphopenic hosts
    Sergio A Quezada
    Ludwig Center for Cancer Immunotherapy, Howard Hughes Medical Institute, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    J Exp Med 207:637-50. 2010
    ....
  3. pmc Tissue-specific expression of B7x protects from CD4 T cell-mediated autoimmunity
    Joyce Wei
    Howard Hughes Medical Institute, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA
    J Exp Med 208:1683-94. 2011
    ..Data from these two autoimmune models provide evidence that B7x expression in the periphery acts as an immune checkpoint to prevent tissue-specific autoimmunity...
  4. pmc Combination CTLA-4 blockade and 4-1BB activation enhances tumor rejection by increasing T-cell infiltration, proliferation, and cytokine production
    Michael A Curran
    Howard Hughes Medical Institute, Department of Immunology, Memorial Sloan Kettering Cancer Center, New York, New York, United States of America
    PLoS ONE 6:e19499. 2011
    ..Antibodies which block CTLA-4 or which activate 4-1BB can promote the rejection of some murine tumors, but fail to cure poorly immunogenic tumors like B16 melanoma as single agents...
  5. pmc Attenuated T cell responses to a high-potency ligand in vivo
    Emily Corse
    Department of Immunology, Howard Hughes Medical Institute and Ludwig Center for Cancer Immunotherapy, Memorial Sloan Kettering Cancer Center, New York, New York, USA
    PLoS Biol 8:. 2010
    ..Our results reveal a level of control over T cell activation in vivo not recapitulated in in vitro assays and highlight the importance of considering in vivo efficacy of TCR ligands as part of vaccine design...
  6. pmc TCR ligand density and affinity determine peripheral induction of Foxp3 in vivo
    Rachel A Gottschalk
    Department of Immunology, Howard Hughes Medical Institute, New York, NY 10021, USA
    J Exp Med 207:1701-11. 2010
    ..However, in the persistence of induced Foxp3(+) T cells, TCR ligand potency and density are noninterchangeable factors that influence the route to peripheral tolerance...
  7. pmc Blockade of CTLA-4 on both effector and regulatory T cell compartments contributes to the antitumor activity of anti-CTLA-4 antibodies
    Karl S Peggs
    Howard Hughes Medical Institute, Department of Immunology, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    J Exp Med 206:1717-25. 2009
    ....
  8. pmc Cancer classification using the Immunoscore: a worldwide task force
    Jerome Galon
    INSERM, U872, Laboratory of Integrative Cancer Immunology, Paris, F 75006, France
    J Transl Med 10:205. 2012
    ..The results of this international validation may result in the implementation of the Immunoscore as a new component for the classification of cancer, designated TNM-I (TNM-Immune)...
  9. pmc Defining the critical hurdles in cancer immunotherapy
    Bernard A Fox
    Earle A, Chiles Research Institute, Robert W, Franz Research Center, Providence Cancer Center, Providence Portland Medical Center, Portland, OR, USA
    J Transl Med 9:214. 2011
    ..Each of these hurdles can significantly delay clinical translation of promising advances in immunotherapy yet if overcome, have the potential to improve outcomes of patients with cancer...
  10. pmc SPAS-1 (stimulator of prostatic adenocarcinoma-specific T cells)/SH3GLB2: A prostate tumor antigen identified by CTLA-4 blockade
    Marcella Fassò
    Departments of Urology and Medicine, University of California, San Francisco, CA 94143, USA
    Proc Natl Acad Sci U S A 105:3509-14. 2008
    ..Our findings demonstrate that our in vivo CTLA-4 blockade-based T cell expression cloning can identify immunogenic cancer antigens with potential relevance for human immunotherapy...
  11. ncbi Principles and use of anti-CTLA4 antibody in human cancer immunotherapy
    Karl S Peggs
    Howard Hughes Medical Institute, Department of Immunology, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY 10021, USA
    Curr Opin Immunol 18:206-13. 2006
    ..Finding ways to dissociate antitumor activity from adverse immune events should enable actualization of their therapeutic potential in the coming years...
  12. pmc CTLA4 blockade and GM-CSF combination immunotherapy alters the intratumor balance of effector and regulatory T cells
    Sergio A Quezada
    Howard Hughes Medical Institute, Department of Immunology, Memorial Sloan Kettering Cancer Center, New York, New York, USA
    J Clin Invest 116:1935-45. 2006
    ....
  13. ncbi CTLA-4 overexpression inhibits T cell responses through a CD28-B7-dependent mechanism
    John J Engelhardt
    Division of Immunology, Howard Hughes Medical Institute, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    J Immunol 177:1052-61. 2006
    ..Our data confirm the activity of CTLA-4 as a negative regulator of T cell activation and that its action may be by multiple mechanisms...
  14. pmc Biologic activity of cytotoxic T lymphocyte-associated antigen 4 antibody blockade in previously vaccinated metastatic melanoma and ovarian carcinoma patients
    F Stephen Hodi
    Department of Adult Oncology, Dana Farber Cancer Institute and Department of Medicine, Brigham and Women s Hospital and Harvard Medical School, Boston, MA 02115, USA
    Proc Natl Acad Sci U S A 100:4712-7. 2003
    ..These findings suggest that CTLA-4 antibody blockade increases tumor immunity in some previously vaccinated cancer patients...
  15. ncbi Systemic CTLA-4 blockade ameliorates glioma-induced changes to the CD4+ T cell compartment without affecting regulatory T-cell function
    Peter E Fecci
    Division of Neurosurgery, Department of Surgery, Duke University Medical Center, Durham, North Carolina 27710, USA
    Clin Cancer Res 13:2158-67. 2007
    ..Our murine glioma model recapitulates these findings. Here, we investigate the effects of systemic CTLA-4 blockade in this model...
  16. ncbi Targeting immunosupportive cancer therapies: accentuate the positive, eliminate the negative
    Karl S Peggs
    Ludwig Center for Cancer Immunotherapy, Howard Hughes Medical Institute, 1275 York Avenue, New York, NY 10021, USA
    Cancer Cell 12:192-9. 2007
    ..We argue for combinatorial strategies with agents that target tumor cells to release these antigens together with innovative therapies that enhance immunological responses by interfering with inhibitory checkpoints...
  17. ncbi The B7 family and cancer therapy: costimulation and coinhibition
    Xingxing Zang
    Howard Hughes Medical Institute, Immunology Program, Ludwig Center of Cancer Immunotherapy, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
    Clin Cancer Res 13:5271-9. 2007
    ..Therefore, the manipulation of these pathways is crucial for developing effective tumor immunotherapy. Translation of our basic knowledge of costimulation and coinhibition into early clinical trials has shown considerable promise...
  18. doi Local secretion of anti-CTLA-4 enhances the therapeutic efficacy of a cancer immunotherapy with reduced evidence of systemic autoimmunity
    Andrew D Simmons
    Cell Genesys, Inc, 500 Forbes Blvd, South San Francisco, CA 94080, USA
    Cancer Immunol Immunother 57:1263-70. 2008
    ..This approach has broad utility for the delivery of mAbs or proteins locally from cellular immunotherapies to minimize IBEs while retaining the potent therapeutic effects of such combination treatments...
  19. doi Cell intrinsic mechanisms of T-cell inhibition and application to cancer therapy
    Karl S Peggs
    Department of Haematology, UCL Cancer Institute, University College London, London, UK
    Immunol Rev 224:141-65. 2008
    ....
  20. pmc Anti-cytotoxic T lymphocyte antigen-4 (CTLA-4) immunotherapy for the treatment of prostate cancer
    R Houston Thompson
    Department of Urology, Mayo Clinic and Mayo Medical School, Rochester, MN 55905, USA
    Urol Oncol 24:442-7. 2006
    ..We review the preclinical and clinical experience with CTLA-4 blockade as a promising immunotherapeutic approach to treat patients with advanced prostate cancer...
  21. ncbi Co-stimulatory pathways in lymphocyte regulation: the immunoglobulin superfamily
    Karl S Peggs
    Department of Immunology, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    Br J Haematol 130:809-24. 2005
    ....
  22. pmc Cancer regression and autoimmunity induced by cytotoxic T lymphocyte-associated antigen 4 blockade in patients with metastatic melanoma
    Giao Q Phan
    Surgery Branch, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA
    Proc Natl Acad Sci U S A 100:8372-7. 2003
    ..This study establishes CTLA-4 as an important molecule regulating tolerance to "self" antigens in humans and suggests a role for CTLA-4 blockade in breaking tolerance to human cancer antigens for cancer immunotherapy...
  23. ncbi BTLA is a lymphocyte inhibitory receptor with similarities to CTLA-4 and PD-1
    Norihiko Watanabe
    Department of Pathology and Immunology, Howard Hughes Medical Institute, Washington University School of Medicine, Box 8118, 660 South Euclid Avenue, St Louis, Missouri 63110, USA
    Nat Immunol 4:670-9. 2003
    ..B7x, a peripheral homolog of B7, is a ligand of BTLA. Thus, BTLA is a third inhibitory receptor on T lymphocytes with similarities to cytotoxic T lymphocyte-associated antigen 4 (CTLA-4) and programmed death 1 (PD-1)...
  24. ncbi B7-1 and B7-2 selectively recruit CTLA-4 and CD28 to the immunological synapse
    Tsvetelina Pentcheva-Hoang
    Department of Molecular and Cell Biology, Cancer Research Laboratory, Howard Hughes Medical Institute, University of California, Berkeley, 94720, USA
    Immunity 21:401-13. 2004
    ....
  25. ncbi CTLA-4 blockade in combination with xenogeneic DNA vaccines enhances T-cell responses, tumor immunity and autoimmunity to self antigens in animal and cellular model systems
    Polly D Gregor
    Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY 10021, USA
    Vaccine 22:1700-8. 2004
    ..Based on these pre-clinical studies, we suggest that anti-CTLA-4 should be tested with xenogeneic DNA vaccines against cancer and that special attention should be given to sequence and schedule of administration...
  26. pmc B7x: a widely expressed B7 family member that inhibits T cell activation
    Xingxing Zang
    Howard Hughes Medical Institute, Department of Molecular and Cell Biology, Cancer Research Laboratory, University of California, Berkeley, CA 94720, USA
    Proc Natl Acad Sci U S A 100:10388-92. 2003
    ..These studies identify a costimulatory pathway that may have a unique function in downregulation of tissue-specific autoimmunity and antitumor responses...
  27. ncbi B7 expression on T cells down-regulates immune responses through CTLA-4 ligation via T-T interactions [corrections]
    Patricia A Taylor
    Cancer Center and Department of Pediatrics, Division of Bone Marrow Transplantation, University of Minnesota, 425 East River Road, Minneapolis, MN 55455, USA
    J Immunol 172:34-9. 2004
    ..The up-regulation of B7 on T cells may be an important component of normal immune homeostasis...
  28. ncbi CTLA-4: new insights into its biological function and use in tumor immunotherapy
    Jackson G Egen
    Howard Hughes Medical Institute, Department of Molecular and Cell Biology, Cancer Research Laboratory, University of California at Berkeley, Berkeley, CA 94720, USA
    Nat Immunol 3:611-8. 2002
    ..We also describe preclinical and clinical results that indicate manipulation of CTLA-4 has considerable promise as a strategy for the immunotherapy of cancer...
  29. ncbi The lymphoproliferative defect in CTLA-4-deficient mice is ameliorated by an inhibitory NK cell receptor
    Cynthia A Chambers
    Department of Pathology, University of Massachusetts Medical School, Worcester, 01655, USA
    Blood 99:4509-16. 2002
    ..These results demonstrate the importance of inhibitory signals in T-cell homeostasis and suggest the common biochemical basis of inhibitory signaling pathways in T lymphocytes...
  30. ncbi Augmentation of T cell levels and responses induced by androgen deprivation
    Anja C Roden
    Department of Urology, Comprehensive Cancer Center, Mayo Clinic, 200 First Street SW, Rochester, MN 55905, USA
    J Immunol 173:6098-108. 2004
    ..Such alterations induced by androgen deprivation may have implications for enhancing immune responses to immunotherapy and for accelerating the recovery of the immune system following chemotherapy...
  31. ncbi Engagement of NKG2D by cognate ligand or antibody alone is insufficient to mediate costimulation of human and mouse CD8+ T cells
    Lauren I Richie Ehrlich
    Department of Microbiology and Immunology and the Cancer Research Institute, University of California, San Francisco, CA 94143, USA
    J Immunol 174:1922-31. 2005
    ..It is, therefore, likely that NKG2D acts as a costimulatory molecule only under restricted conditions or requires additional cofactors...
  32. ncbi Immune-mediated inhibition of metastases after treatment with local radiation and CTLA-4 blockade in a mouse model of breast cancer
    Sandra Demaria
    Department of Pathology, New York University School of Medicine, 550 First Avenue, New York, NY 10016, USA
    Clin Cancer Res 11:728-34. 2005
    ..Here we tested the hypothesis that the combination of RT to the primary tumor with CTLA-4 blockade can elicit antitumor immunity inhibiting the metastases...
  33. pmc Cytotoxic T lymphocyte antigen-4 (CTLA-4) limits the expansion of encephalitogenic T cells in experimental autoimmune encephalomyelitis (EAE)-resistant BALB/c mice
    Arthur A Hurwitz
    Department of Microbiology and Immunology, State University of New York Upstate Medical University, Syracuse, NY 13210, USA
    Proc Natl Acad Sci U S A 99:3013-7. 2002
    ....
  34. ncbi Cytotoxic T lymphocyte antigen-4 accumulation in the immunological synapse is regulated by TCR signal strength
    Jackson G Egen
    Howard Hughes Medical Institute, Department of Molecular and Cell Biology, Cancer Research Laboratory, University of California at Berkeley, Berkeley, CA 94720, USA
    Immunity 16:23-35. 2002
    ..This may represent a novel feedback control mechanism in which a stimulatory signal regulates the recruitment of an inhibitory receptor to a functionally relevant site on the cell surface...
  35. pmc Inducible costimulator is required for type 2 antibody isotype switching but not T helper cell type 2 responses in chronic nematode infection
    P ng Loke
    Department of Pathology, University of California San Francisco, San Francisco, CA 94143, USA
    Proc Natl Acad Sci U S A 102:9872-7. 2005
    ..The primary role of ICOS in a chronic helminth infection could be to drive antibodies toward type 2 isotypes. T-independent antibody response to the parasite could be enhanced in the absence of costimulation and T cell help...
  36. pmc CTLA4 blockade expands FoxP3+ regulatory and activated effector CD4+ T cells in a dose-dependent fashion
    Brian Kavanagh
    Department of Microbiology and Immunology, Division of Hematology Oncology, University of California, San Francisco, CA 94143, USA
    Blood 112:1175-83. 2008
    ..Our results also suggest that CTLA4 may inhibit Treg proliferation similar to its role on effector T cells. This study is registered at http://www.clinicaltrials.gov/ct2/show/NCT00064129, registry number NCT00064129...
  37. ncbi Prostate cancer: advances in immunotherapy
    Arthur A Hurwitz
    Department of Microbiology, SUNY Upstate Medical University, Syracuse, NY, USA
    BioDrugs 17:131-8. 2003
    ..Nevertheless, further basic and clinical investigation is still required to establish immunotherapy as a true prostate cancer treatment option...
  38. pmc Regulated costimulation in the thymus is critical for T cell development: dysregulated CD28 costimulation can bypass the pre-TCR checkpoint
    Joy A Williams
    Experimental Immunology Branch, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA
    J Immunol 175:4199-207. 2005
    ....
  39. ncbi Cutting edge: a crucial role for B7-CD28 in transmitting T help from APC to CTL
    Kiley R Prilliman
    Division of Immune Regulation, La Jolla Institute for Allergy and Immunology, 10355 Science Center Drive, San Diego, CA 92121, USA
    J Immunol 169:4094-7. 2002
    ..These results support a model in which activation-induced up-regulation of B7 molecules on APC leads to increased CD28 signaling and a commitment to cross-priming of CD4-dependent CTL...
  40. ncbi CD28 disruption exacerbates inflammation in Tgf-beta1-/- mice: in vivo suppression by CD4+CD25+ regulatory T cells independent of autocrine TGF-beta1
    Mizuko Mamura
    Laboratory of Cell Regulation and Carcinogenesis, National Cancer Institute, National Institutes of Health, Bldg 41, 41 Library Drive MSC 5055, Bethesda, MD 20892 5055, USA
    Blood 103:4594-601. 2004
    ....
  41. doi Recognition of a ubiquitous self antigen by prostate cancer-infiltrating CD8+ T lymphocytes
    Peter A Savage
    Department of Immunology, Howard Hughes Medical Institute, and Ludwig Center for Cancer Immunotherapy, Memorial Sloan Kettering Cancer Center MSKCC, New York, NY 10021, USA
    Science 319:215-20. 2008
    ..Thus, the repertoire of antigens recognized by tumor-infiltrating T cells is broader than previously thought and includes peptides derived from ubiquitous self antigens that are normally sequestered from immune detection...
  42. ncbi Breaking down the barriers to cancer immunotherapy
    Ellen Pure
    Wistar Institute and The Ludwig Institute for Cancer, Philadelphia, Pennsylvania 19104, USA
    Nat Immunol 6:1207-10. 2005
    ..Emerging insights into the mechanisms of activation and negative regulation of innate and adaptive immune cells are providing new opportunities for the development of safe and effective cancer vaccines...
  43. ncbi Restoring function in exhausted CD8 T cells during chronic viral infection
    Daniel L Barber
    Emory Vaccine Center and Department of Microbiology and Immunology, Emory University School of Medicine, Atlanta, Georgia 30322, USA
    Nature 439:682-7. 2006
    ..These studies identify a specific mechanism of T-cell exhaustion and define a potentially effective immunological strategy for the treatment of chronic viral infections...
  44. pmc Emerging mechanisms of immune regulation: the extended B7 family and regulatory T cells
    P ng Loke
    Howard Hughes Medical Institute, University of California, Berkeley, Berkeley, CA, USA
    Arthritis Res Ther 6:208-14. 2004
    ..The different varieties of regulatory T cells could regulate both naive T cell activation and effector function through costimulatory receptor/ligands...
  45. ncbi A genetic library screen for signaling proteins that interact with phosphorylated T cell costimulatory receptors
    Xingxing Zang
    Howard Hughes Medical Institute, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    Genomics 88:841-5. 2006
    ..The p85 unit of PI3K is the only signaling molecule identified so far that interacts with ICOS. This system may be of great help in dissecting the mechanisms of T cell costimulation and could be applied to other receptors...
  46. pmc To be or not to be B7
    Xingxing Zang
    Immunology Program, Howard Hughes Medical Institute, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
    J Clin Invest 116:2590-3. 2006
    ..These findings raise interesting questions regarding the physiological roles and mechanisms of action of this molecule. Identification of dual functions of this molecule provides an additional level of complexity in T cell costimulation...
  47. ncbi A pilot trial of CTLA-4 blockade with human anti-CTLA-4 in patients with hormone-refractory prostate cancer
    Eric J Small
    UCSF Comprehensive Cancer Center, University of California San Francisco, San Francisco, CA 94115, USA
    Clin Cancer Res 13:1810-5. 2007
    ....
  48. ncbi Immunotherapeutic strategies for high-risk bladder cancer
    Padmanee Sharma
    Department of Genitourinary Medical Oncology and Immunology, The University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
    Semin Oncol 34:165-72. 2007
    ..In this review, we discuss the complexity of the immune system and therapies that are considered capable of manipulating it to potentially benefit patients with bladder cancer...
  49. pmc Functional deficiencies of granulocyte-macrophage colony stimulating factor and interleukin-3 contribute to insulitis and destruction of beta cells
    Thomas Enzler
    Department of Medical Oncology, Dana Farber Cancer Institute, 44 Binney Street, Boston, MA 02115, USA
    Blood 110:954-61. 2007
    ..These results, together with previous reports of impaired hematopoietic responses to GM-CSF and IL-3 in patients with T1D and in NOD mice, indicate that functional deficiencies of these cytokines contribute to diabetes...
  50. ncbi MHC class II-independent and -dependent T cell expansion and B cell hyperactivity in vivo in mice deficient in CD152 (CTLA-4)
    William Stohl
    Division of Rheumatology, Department of Medicine, University of Southern California Keck School of Medicine, Los Angeles, CA 90033, USA
    Int Immunol 16:895-904. 2004
    ....
  51. ncbi Alternative activation is an innate response to injury that requires CD4+ T cells to be sustained during chronic infection
    P ng Loke
    Tropical Disease Research Unit, University of California, San Francisco, CA 94143, USA
    J Immunol 179:3926-36. 2007
    ..However, analogous to classical activation by microbial pathogens, Th2 cells are required for maintenance and full activation during the ongoing response to metazoan parasites...
  52. pmc Programmed death-1 concentration at the immunological synapse is determined by ligand affinity and availability
    Tsvetelina Pentcheva-Hoang
    Howard Hughes Medical Institute, Department of Immunology, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    Proc Natl Acad Sci U S A 104:17765-70. 2007
    ..PD-1 and CD28 have similar kinetics of synaptic accumulation, suggesting that the process involves T cell receptor-triggered cytoskeletal reorganization followed by ligand binding...
  53. pmc B7-H3 and B7x are highly expressed in human prostate cancer and associated with disease spread and poor outcome
    Xingxing Zang
    Howard Hughes Medical Institute, Immunology Program and Ludwig Center for Cancer Immunotherapy, and Departments of Surgery and Urology, Pathology, and Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA
    Proc Natl Acad Sci U S A 104:19458-63. 2007
    ..Given the proposed immune-inhibitory mechanisms of B7-H3 and B7x, these molecules represent attractive targets for therapeutic manipulation in prostate cancer...
  54. pmc Immunologic and clinical effects of antibody blockade of cytotoxic T lymphocyte-associated antigen 4 in previously vaccinated cancer patients
    F Stephen Hodi
    Department of Medical Oncology and Cancer Vaccine Center, Dana Farber Cancer Institute, Brigham and Women s Hospital and Harvard Medical School, 44 Binney Street, Boston, MA 02115, USA
    Proc Natl Acad Sci U S A 105:3005-10. 2008
    ....

Research Grants3

  1. T CELL COSTIMULATION IN ANTITUMOR RESPONSES
    James Allison; Fiscal Year: 2001
    ..5.Examine the possibility that autoimmunity might accompany tumor rejection induced by CTLA-4 blockade. ..
  2. High Speed Cell Sorter
    James Allison; Fiscal Year: 2002
    ..abstract_text> ..
  3. SURFACE ANTIGENS OF MURINE T LYMPHOMAS
    James Allison; Fiscal Year: 2008
    ..3) Determine the role of B7x in regulating immune responses in vivo. 4) Identify and characterize T cell receptor(s) for B7x. ..